A Phase 1/2 interventional study of SHR7280 and Placebo oral tablet in Endometriosis, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-07-08.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Endometriosis with a site in China — 16 open to participants now, 17 under way, 2 of them phase 3. Endometriosis · China.
Among the 47 studies in Endometriosis with a site in China, this one is the 14th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2020, is the only one in phase 1/2, and was the 17th registered.
921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.
Browse Endometriosis studies →16 of the 47 studies in Endometriosis with a site in China are open now. Recruiting first, the newest first:
Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18–45 · Women only
Catherin Zhang · Sites in China
Ages 18–75 · Women only
Obstetrics & Gynecology Hospital of Fudan University · Sites in China
Ages 18–55 · Women only
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18–50 · Women only
Li Li · Sites in China
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 6 · Phase 4 3
First in 2008; this study’s year is marked. 3 started in 2020.
This study's enrollment of 179 is above the median of 67 across 541 interventional studies indexed under Endometriosis.
Median enrollment 161 across the 28 interventional studies, 402 across the 19 observational. Of the 16 that completed or were terminated, 3 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 47 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Jiangsu HengRui Medicine Co., Ltd. has 4 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Endometriosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07860203Catherin ZhangStellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery | 2026-12 |
| NCT06266897Zhujiang HospitalA Study on the Correlation Between Endometriosis and Intra-tissue Microbiota | 2026-12 |
| NCT07014761Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThe Influence of Central Sensitization in Endometriosis Disease | 2027-03-31 |
| NCT07755956Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis | 2027-03-31 |
| NCT06584760The Fourth Affiliated Hospital of Zhejiang University School of MedicineResearch on the Impact of Chronic Pelvic Pain on Endometriosis | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 47 studies in Endometriosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR7280 tablets in premenopausal subjects with endometriosis. In addition, this study will provide information on efficacy of SHR7280 tablets in premenopausal subjects with endometriosis.
Endometriosis is a common disease, affecting 5-10% of women of reproductive age . It is an estrogen-dependent and estrogen-driven disease and so hormonal manipulation and suppression of estrogen production form the basis of the majority of medical treatment. The primary objective of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR7280 tablets in premenopausal subjects with endometriosis. In addition, this study will provide information on efficacy of SHR7280 tablets in premenopausal subjects with endometriosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase I/II
Phase II(only) Participant has moderate or severe pelvic pain associated with endometriosis at Screening.
Exclusion Criteria:
Phase I/II
Phase I (only) one month prior to screening involved in any drug or medical device clinical subjects, or within 5 half-life of drugs before screening; Phase II (only) Screening dual-energy x-ray absorptiometry (DXA) scan results of the lumbar spine, femoral neck, or total hip bone mineral density corresponding to 1.5 or more standard deviations below normal (T-score at or below -1.5)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
oral administration for 21days,Phase I
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 21days,Phase I
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 21days,Phase I
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 21days,Phase I
Drug: SHR7280 · Drug: Placebo oral tablet
oral administration for 84days,Phase II
Drug: SHR7280
oral administration for 84days, Phase II
Drug: SHR7280
oral administration for 84days, Phase II
Drug: Placebo oral tablet
treatment
blank control
Number of Participants with Adverse events
Phase I
Time frame: Pre-dose to 28±2 days after dose administration
Change From Baseline in the 7-day mean score for pelvic pain as measured by VAS at weeks 12
Phase II daily assessment of dysmenorrhea score on a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) using an e-Diary.
Time frame: Baseline and weeks 12
PK markers of SHR7280: area under the plasma concentration versus time curve (AUC)
Phase I \& II
Time frame: At pre-defined intervals from initial dose through final study visit
PK markers of SHR7280: time to maximum plasma concentration(Tmax)
Phase I \& II
Time frame: At pre-defined intervals from initial dose through final study visit
PK markers of SHR7280: maximum plasma concentration(Cmax)
Phase I \& II
Time frame: At pre-defined intervals from initial dose through final study visit
PK markers of SHR7280: half-time(t1/2)
Phase I \& II
Time frame: At pre-defined intervals from initial dose through final study visit
PK markers of SHR7280: apparent clearance(CL/F)
Phase I \& II
Time frame: At pre-defined intervals from initial dose through final study visit
PK markers of SHR7280: apparent volume of distribution(Vz/F)
Phase I \& II
Time frame: At pre-defined intervals from initial dose through final study visit
PD markers of SHR7280: Concentration of Estradiol(E2)
Phase I \& II
Time frame: At pre-defined intervals from initial dose through final study visit
PD markers of SHR7280: Concentration of Progesterone(P)
Phase I \& II
Time frame: At pre-defined intervals from initial dose through final study visit
PD markers of SHR7280: Concentration of Follicle stimulating hormone(FSH)
Phase I \& II
Time frame: At pre-defined intervals from initial dose through final study visit
PD markers of SHR7280: Concentration of Luteinizing hormone(LH)
Phase I \& II
Time frame: At pre-defined intervals from initial dose through final study visit
Change From Baseline in the 7-day mean score for pelvic pain as measured by VAS
Phase II
Time frame: Baseline and weeks 4、8
Change From Baseline in the Monthly Mean score for pelvic pain as measured by VAS
Phase II
Time frame: Baseline and weeks 4、8、12
Change From Baseline in the Monthly Mean Dysmenorrhea Score
Phase II
Time frame: Baseline and weeks 8、12
Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score and Dyspareunia Score
Phase II
Time frame: Baseline and weeks 4、8、12
Change from baseline to monthly analgesic use to treat endometriosis-associated pain
Phase II
Time frame: Baseline and weeks 4、8、12
Patient Global Impression of Change (PGIC) score at week 12
Phase II
Time frame: Week 12
Adverse events
Time frame: during Pre and 28±3 days after dose administration
Ran from Jul 2020 to primary completion in May 2024, 45 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GnRH Antagonist SHR7280
Jiangsu HengRui Medicine Co., Ltd. →